



Surgical Treatment of Hepatocellular Carcinoma

Guest Editor:

Prof. Dr. Wei-Chen Lee

Department of General Surgery
and Chang Gung Transplantation
Institute, Chang Gung Memorial
Hospital at Linkou, Chang Gung
University College of Medicine,
Taoyuan 33302, Taiwan

Deadline for manuscript
submissions:

31 January 2025

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Surgical treatment remains the most important treatment for HCC. Traditionally, surgical treatment is limited to treating the early stages of HCC. However, most cases of HCC are found at the late stages. Whether surgical treatment has a role in the treatment of HCC beyond the early stage is an important issue.

This Special Issue entitled “Surgical Treatment of Hepatocellular Carcinoma” focuses on the innovation of surgical treatments. We are pleased to invite you to submit manuscripts to this Special Issue. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: surgical techniques, surgical indications, surgical outcomes, clinical trials, liver transplantation, adjuvant therapy, basic research, etc.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)